Nautilus Biotechnology (NAUT) Current Assets (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Current Assets of $87.6 million for Q2 2026, down 11.34% sequentially from $98.8 million in Q1 2026, and down 41.86% YoY from $150.7 million in Q2 2025.
Nautilus Biotechnology (NAUT) Current Assets (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Current Assets for 7 years, with the latest figure at $87.6 million in Q2 2026.
- Quarterly Current Assets fell 41.86% year-over-year to $87.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $87.6 million (down 41.86% YoY) and the FY2025 annual result came in at $106.0 million, down 20.22% from the prior year.
- Current Assets eased to $87.6 million in Q2 2026 per NAUT's latest filing, from $98.8 million in the prior quarter.
- Over five years, Current Assets peaked at $327.1 million in Q1 2022 and troughed at $87.6 million in Q2 2026.
- A 5-year average of $174.0 million and a median of $168.6 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets jumped 34856.29% in 2022, then sank 47.87% in 2023.
- Over 5 years, Current Assets stood at $187.2 million in 2022, then retreated by 5.54% to $176.8 million in 2023, then declined by 24.89% to $132.8 million in 2024, then fell by 20.22% to $106.0 million in 2025, then declined by 17.31% to $87.6 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $87.6 million, $98.8 million, and $106.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | 87.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.63 Mn |
| Mar 31, 2026 | 98.83 Mn |
| Dec 31, 2025 | 105.96 Mn |
| Sep 30, 2025 | 134.33 Mn |
| Jun 30, 2025 | 150.73 Mn |
| Mar 31, 2025 | 141.60 Mn |
| Dec 31, 2024 | 132.83 Mn |
| Sep 30, 2024 | 144.21 Mn |
| Jun 30, 2024 | 170.93 Mn |
| Mar 31, 2024 | 185.09 Mn |
| Dec 31, 2023 | 176.84 Mn |
| Sep 30, 2023 | 186.79 Mn |
| Jun 30, 2023 | 166.70 Mn |
| Mar 31, 2023 | 170.48 Mn |
| Dec 31, 2022 | 187.21 Mn |
| Sep 30, 2022 | 261.22 Mn |
| Jun 30, 2022 | 303.45 Mn |
| Mar 31, 2022 | 327.07 Mn |
| Dec 31, 2021 | 349.22 Mn |
| Sep 30, 2021 | 352.22 Mn |